Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak.

Gain valuable insights into the Livestock Monitoring Market with the Livestock Monitoring Companies Quadrant, an in-depth industry analysis identifying technological advancements, product innovations, ...

If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.

DelveInsight's,“ Fallopian Tube Cancer Pipeline Insight 2025 ” report provides comprehensive insights about 70+ Fallopian ...

Merck & Co., Inc. recently reported robust earnings, yet the market response was lukewarm. Investors overlooked several positive aspects beneath the surface. Unusual expenses, totaling US$4.2 billion, ...

Adagene ( ($ADAG) ) has provided an update. On August 12, 2025, Adagene Inc. announced its financial results for the first half of 2025, ...

Exelixis(EXEL) is developing zanzalintinib— a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhibits the activity of receptor tyrosine kinases implicated in cancer ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Calm prevailed across Wall Street as an in-line inflation reading bolstered speculation the Federal Reserve will have room to ...